Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q13285
UPID:
STF1_HUMAN
Alternative names:
Adrenal 4-binding protein; Fushi tarazu factor homolog 1; Nuclear receptor subfamily 5 group A member 1; Steroid hormone receptor Ad4BP
Alternative UPACC:
Q13285; O15196; Q5T6F5
Background:
Steroidogenic factor 1 (SF-1), also known as Adrenal 4-binding protein and Nuclear receptor subfamily 5 group A member 1, plays a pivotal role in sexual differentiation and the formation of primary steroidogenic tissues. It activates transcription by binding to specific DNA sequences, influencing genes critical for steroid hormone production and reproductive system development.
Therapeutic significance:
SF-1 is linked to various disorders, including 46,XY sex reversal 3, 46,XX sex reversal 4, adrenal insufficiency, premature ovarian failure, and spermatogenic failure. Understanding SF-1's role could unveil new therapeutic strategies for these conditions.